These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 25332338)

  • 1. Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study.
    Ix JH; Anderson CA; Smits G; Persky MS; Block GA
    Am J Clin Nutr; 2014 Nov; 100(5):1392-7. PubMed ID: 25332338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
    Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
    J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
    Ix JH; Isakova T; Larive B; Raphael KL; Raj DS; Cheung AK; Sprague SM; Fried LF; Gassman JJ; Middleton JP; Flessner MF; Block GA; Wolf M
    J Am Soc Nephrol; 2019 Jun; 30(6):1096-1108. PubMed ID: 31085679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial.
    Sigrist M; Tang M; Beaulieu M; Espino-Hernandez G; Er L; Djurdjev O; Levin A
    Nephrol Dial Transplant; 2013 Jan; 28(1):161-9. PubMed ID: 23024219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.
    Isakova T; Barchi-Chung A; Enfield G; Smith K; Vargas G; Houston J; Xie H; Wahl P; Schiavenato E; Dosch A; Gutiérrez OM; Diego J; Lenz O; Contreras G; Mendez A; Weiner RB; Wolf M
    Clin J Am Soc Nephrol; 2013 Jun; 8(6):1009-18. PubMed ID: 23471131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
    Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
    Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients.
    Soriano S; Ojeda R; Rodríguez M; Almadén Y; Rodríguez M; Martín-Malo A; Aljama P
    Clin Nephrol; 2013 Jul; 80(1):17-22. PubMed ID: 23391319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD.
    Malhotra R; Katz R; Hoofnagle A; Bostom A; Rifkin DE; Mcbride R; Probstfield J; Block G; Ix JH
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):36-44. PubMed ID: 29208626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circadian rhythm of activin A and related parameters of mineral metabolism in normal and uremic rats.
    Nordholm A; Egstrand S; Gravesen E; Mace ML; Morevati M; Olgaard K; Lewin E
    Pflugers Arch; 2019 Aug; 471(8):1079-1094. PubMed ID: 31236663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol.
    Isakova T; Xie H; Barchi-Chung A; Smith K; Sowden N; Epstein M; Collerone G; Keating L; Jüppner H; Wolf M
    Clin J Am Soc Nephrol; 2012 May; 7(5):820-8. PubMed ID: 22383746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal Phosphorus Absorption in Moderate CKD and Healthy Adults Determined Using a Radioisotopic Tracer.
    Stremke ER; Wiese GN; Moe SM; Wastney ME; Moorthi RN; Hill Gallant KM
    J Am Soc Nephrol; 2021 Aug; 32(8):2057-2069. PubMed ID: 34244325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes modifies effect of high-phosphate diet on fibroblast growth factor-23 in chronic kidney disease.
    Muras K; Masajtis-Zagajewska A; Nowicki M
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1901-8. PubMed ID: 24092829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
    Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorus Additives and Albuminuria in Early Stages of CKD: A Randomized Controlled Trial.
    Chang AR; Miller ER; Anderson CA; Juraschek SP; Moser M; White K; Henry B; Krekel C; Oh S; Charleston J; Appel LJ
    Am J Kidney Dis; 2017 Feb; 69(2):200-209. PubMed ID: 27865566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acid Load and Phosphorus Homeostasis in CKD.
    Khairallah P; Isakova T; Asplin J; Hamm L; Dobre M; Rahman M; Sharma K; Leonard M; Miller E; Jaar B; Brecklin C; Yang W; Wang X; Feldman H; Wolf M; Scialla JJ;
    Am J Kidney Dis; 2017 Oct; 70(4):541-550. PubMed ID: 28645705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial.
    Tsai WC; Wu HY; Peng YS; Hsu SP; Chiu YL; Yang JY; Chen HY; Pai MF; Lin WY; Hung KY; Chu FY; Tsai SM; Chien KL
    Clin J Am Soc Nephrol; 2019 Oct; 14(10):1475-1483. PubMed ID: 31519550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
    BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.
    Ruggiero B; Trillini M; Tartaglione L; Rotondi S; Perticucci E; Tripepi R; Aparicio C; Lecchi V; Perna A; Peraro F; Villa D; Ferrari S; Cannata A; Mazzaferro S; Mallamaci F; Zoccali C; Bellasi A; Cozzolino M; Remuzzi G; Ruggenenti P; Kohan DE;
    Am J Kidney Dis; 2019 Sep; 74(3):338-350. PubMed ID: 31027883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the Potassium-Binding Polymer Patiromer on Markers of Mineral Metabolism.
    Bushinsky DA; Spiegel DM; Yuan J; Warren S; Fogli J; Pergola PE
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):103-110. PubMed ID: 30381412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
    Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
    BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.